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Mortality rates from kidney cancer increased throughout Europe up until the late 1980s or early
1990s. Trends in western European countries, the European Union (EU) and selected central and
eastern European countries have been updated using official death certification data for kidney can-
cer abstracted from the World Health Organisation (WHO) database over the period 1980–1999. In
EU men, death rates increased from 3.92 per 100 000 (age standardised, world standard) in 1980–81
to 4.63 in 1994–95, and levelled off at 4.15 thereafter. In women, corresponding values were 1.86
in 1980–81, 2.04 in 1994–95 and 1.80 in 1998–99. Thus, the fall in kidney cancer mortality over
the last 5 years was over 10% for both sexes in the EU. The largest falls were in countries with
highest mortality in the early 1990s, such as Germany, Denmark and the Netherlands. Kidney cancer
rates levelled off, but remained very high, in the Czech Republic, Baltic countries, Hungary, Poland
and other central European countries. Thus, in the late 1990s, a greater than three-fold difference in
kidney cancer mortality was observed between the highest rates in the Czech Republic, the Baltic
Republics and Hungary, and the lowest ones in Romania, Portugal and Greece. Tobacco smoking is
the best recognised risk factor for kidney cancer, and the recent trends in men, mainly in western
Europe, can be related to a reduced prevalence of smoking among men. Tobacco, however, cannot
account for the recent trends registered in women.
Introduction
Kidney cancer includes renal cell carcinomas, which account
for about two-thirds of cases, transitional cell carcinomas of
renal pelvis and a few rarer neoplasms, such as nephroblasto-
mas in children [1].
Tobacco smoking is strongly related to renal pelvis carci-
nomas, but also—although less strongly—to renal cell carci-
nomas [2–5]. Obesity is another major recognised risk factor
for renal cell carcinomas [1, 3, 4, 6]. The role of other factors,
including phenacetin, diuretics and calcium channel blockers
[7, 8], diet (i.e. a protective role of vegetables and fruit, and
an association with meat, fats and protein) [1, 9, 10], alcohol
drinking [11–13] and selected occupations (i.e. cadmium, dry
cleaning workers [1, 4]) has also been reported, but quantifi-
cation of its impact on national mortality rates remains unde-
fined [14, 15].
Between the mid-1950s and the late 1980s, mortality from
kidney cancer increased substantially across Europe. The aver-
age rise between 1955 and 1989 was 73% in men and 48% in
women, and corresponding figures in the late 1980s were 17%
in men and 16% in women [16]. Incidence of renal cell cancer
also rose between 1975 and 1990 in the USA [17, 18].
In the early 1990s, however, some levelling or decline in
kidney cancer rates has been observed in Sweden and other
Scandinavian countries, France and Switzerland, mostly in
men [19–21].
To further monitor recent trends in Europe, we examined
the trends in mortality observed in various European countries
over the last two decades.
Patients and methods
Official death certification numbers for kidney cancer were derived from
the World Health Organisation (WHO) database over the period 1980–
1999, whenever available. Estimates of the resident population, generally
based on official censuses, were based on the same WHO database (http://
www3.who.int/whsis/menu.cfm).
For this analysis we considered recent trends in mortality from kidney
cancer for 27 individual European countries and the 15 countries of the
European Union (Austria, Belgium, Denmark, Finland, France, Germany,
Greece, Ireland, Italy, Luxembourg, The Netherlands, Portugal, Spain,
Sweden and the UK). Since, up to 1989, data were only available for
former Yugoslavia as a whole, it was not possible to provide long-term
trends for Croatia, Slovenia and other former Yugoslavia countries.
In the 1980s most countries used the ninth revision of the International
Classification of Diseases (ICD), although some were still using the eighth
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revision, and from 1995 onwards some countries had adopted the tenth
revision. Since differences between various revisions were minor, kidney
cancer deaths were re-coded for all countries according to the ninth revi-
sion of the ICD (ICD-9: 189 [22]).
From the matrices of certified deaths and resident population, age-
standardised rates (in 5-year age groups) at all ages and at ages 35–64
years were computed, on the basis of the world standard population.
Results
Figure 1 shows the trends in kidney cancer mortality in the EU
between 1980 and 1999. In men, overall age-standardised
rates increased from 3.92 in 1980–81 to 4.63 per 100 000
in 1994–95, and levelled off thereafter to 4.15 per 100 000
in 1998–99. In women, corresponding values were 1.86 in
1980–81, 2.04 in 1994–95 and 1.80 in 1998–99. Thus, the
fall in the last five calendar years was over 10% in both sexes.
Table 1 gives overall age-standardised rates in 27 separate
European countries and the EU in 1990, 1995 and 1999. Cor-
responding trends in 20 selected major European countries are
given in Figure 2. Substantial falls were observed in western
and northern European countries, with highest rates in the
early 1990s, such as Germany (24% in men and 21% in
women, over the last 5 years), Denmark and the Netherlands.
Kidney cancer mortality declined by 8% in men and 15%
in women, but remained very high in the Czech Republic
(9.9 per 100 000 men, 4.4 per 100 000 women), and was high
in Hungary, the Baltic countries and other central European
countries. In southern Europe (Portugal, Spain, Greece), kid-
ney cancer mortality was low in the early 1990s, but tended to
rise until the mid-1990s and to decline only in more recent
years. The diverging trends in different European geographic
areas led to a levelling of kidney cancer mortality rates across
Europe.
Still, in the late 1990s, a greater than three-fold difference
was observed between the highest rates in the Czech Republic,
the Baltic Republics and Hungary, and the lowest ones in
Romania, Portugal and Greece (Figure 3).
Table 2 gives corresponding values for truncated rates
between the ages 35 and 64 years. In the overall EU truncated
rate, the fall started earlier (6% in men and 3% in women,
between 1990 and 1995), and was similar for men (9%) and
somewhat larger for women (16%) over the last 5-year
calendar period. Also, in those central European countries
with high rates that provided data (Czech Republic, Hungary),
trends in the early 1990s were somewhat more favourable in
middle age, indicating a cohort pattern in kidney cancer
mortality.
Discussion
The present update of kidney cancer mortality in Europe
shows a clear change in trends, with an end to the long-term
rise observed up to the early 1990s [16], and the start of a
decline in rates, not only in Scandinavian countries, but also
in most of western Europe. Consequently, kidney cancer mor-
tality in the EU declined by over 10% over the last 5 years.
The falls started earlier in the middle aged (35–64 years)
population. Similar trends were observed in the USA, where
kidney cancer mortality rates have increased for both sexes
among both Whites and Blacks up until the early 1990s, and
stabilized afterwards [16, 18, 23].
Tobacco smoking is the single best recognised risk factor
for kidney cancer, and particularly for renal pelvis neoplasms,
Figure 1. Trends in overall and at age 35–64 years age-standardised (world population) death certification rates (per 100 000) from kidney cancer in men
and women in the EU, between 1980 and 1999. M, male; F, Female; yrs, years.
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the RR being over 2 for smoking, with a proportional attribu-
table risk of about one-quarter of cancer in men and 10% in
women in developed countries [1, 14–16, 24]. Thus, the
decline in smoking prevalence in men over the last few dec-
ades [25] in most of western Europe may explain, at least in
part, the decline in kidney cancer rates. The pattern of tobacco
consumption across Europe can also explain the less favour-
able trends registered in central and eastern European
countries, with rising smoking prevalence and consumption
and, consequently, rates of tobacco-related diseases have rem-
ained higher than in western Europe over the last decade [26].
Tobacco, however, cannot account for the trends observed in
women.
Obesity, the second best recognised risk factor for kidney
cancer [1, 6, 14, 15], accounted for >20% of cases in a popu-
lation from Minnesota [15]. The prevalence of overweight
and obesity is lower in Europe than in the USA [5, 27], but
overweight and obesity have tended to increase throughout
Europe during the last decades, and thus cannot explain the
favourable trends observed in mortality from kidney cancer.
Dietary factors may play some role but their influence on
renal carcinogenesis remains unclear. Still, a diet poor in fruit
and vegetables, and hence in b-carotene, accounts for 17% of
cases in an Italian dataset [14], and several studies found an
inverse relation between a diet rich in vegetables and fruit,
and kidney cancer [1, 4, 9–11]. A wider availability of fruit
and vegetables across Europe over the last few decades may
therefore have contributed to the favourable trend in kidney
cancer mortality. It is also conceivable that declined exposure
to occupational carcinogens has played some role, although
the impact of occupational exposures on kidney cancer risk
remains unquantified [4, 28]. Likewise, better control of urin-
ary tract infections may have favourably influenced kidney
cancer rates [1, 4, 29].
Table 1. Overall age-adjusted (world population) mortality rates from kidney cancer per 100 000 men and women in separate European countries in
1990, 1995 and 1999, and corresponding change in rates
Men Women








Austria 5.79 5.03 4.91 13.13 2.39 2.58 2.46 2.45 4.65 0.41
Belgium (1992) 4.32 4.51 – 4.40 – 2.19 2.35 – 7.31 –
Bulgaria 2.06 2.28 3.05 10.68 33.77 1.02 1.06 1.05 3.92 0.94
Croatia 3.37 4.65 5.54 37.98 19.14 2.07 1.87 1.87 9.66 0.00
Czech Republic 10.22 10.75 9.89 5.19 8.00 4.73 4.94 4.20 4.44 14.98
Denmark (1998) 5.26 5.02 4.30 4.56 14.34 3.61 2.84 2.73 21.33 3.87
Estonia – 7.51 8.52 – 13.45 – 3.46 3.27 – 5.49
Finland 6.17 4.98 5.04 19.29 1.20 3.10 2.71 2.31 12.58 14.76
France 4.60 4.44 4.42 3.48 0.45 1.79 1.83 1.80 2.23 1.64
Germany 6.14 4.63 1.30 23.60 2.76 2.70 2.14 2.17 20.74
Greece 2.18 2.68 2.82 22.94 5.22 0.86 0.95 1.14 10.47 20.00
Hungary 6.19 6.53 6.90 5.49 5.67 2.60 3.03 3.07 16.54 1.32
Ireland 2.85 2.97 3.78 4.21 27.27 1.58 1.64 1.87 16.54 1.32
Italy 4.21 3.99 3.82 5.23 4.26 1.62 1.52 1.39 6.17 8.55
Lithuania – 8.03 7.06 – 12.08 – 3.24 3.19 – 1.54
Luxembourg 2.69 4.90 2.83 – 42.24 2.30 1.74 1.29 – 25.86
Macedonia – 1.08 2.27 – 110.19 – 0.41 1.06 – 158.54
Malta 4.10 6.13 2.90 49.51 52.69 2.20 1.83 1.60 16.82 12.57
Netherlands 5.39 5.32 4.60 1.30 13.53 2.37 2.56 2.35 8.02 8.20
Norway 4.78 5.03 4.98 5.23 0.99 2.69 2.23 2.10 17.10 5.83
Portugal 1.95 2.46 2.18 26.15 11.38 1.19 0.91 0.86 23.53 5.49
Slovakia – 7.30 6.28 – 13.97 – 2.88 2.95 – 2.43
Slovenia 3.28 3.46 4.58 5.49 32.37 1.62 2.34 2.25 44.44 3.85
Spain 2.71 3.15 2.90 16.24 7.94 0.99 1.25 1.20 26.26 4.00
Sweden 5.07 4.20 4.06 17.16 3.33 3.12 2.86 2.79 8.33 2.45
Switzerland 4.77 3.93 – 17.61 – 2.19 1.74 – 20.55 –
UK 3.96 4.03 4.07 1.77 0.99 1.80 1.94 1.78 7.78 8.25
European Union 4.50 4.45 4.04 1.11 9.21 1.99 2.00 1.76 0.50 12.00
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At least part of the upward trends observed until the early
1990s may be related to improved diagnosis and certification
of the disease, following the introduction of ultrasound,
computed tomography and other newer diagnostic tech-
niques. However, the similar pattern of trends in middle age
(35–64 years) and in the elderly weighs against a major
role of changed diagnosis and certification criteria on kidney
cancer risk, at least in major eastern and central European
countries.
In conclusion, therefore, the present update analysis of
kidney cancer in Europe documents and quantifies an appreci-
able reduction in mortality. The decline in tobacco smoking in
men has played a role in these favourable trends, but the
potential influence of other factors remains undefined.
Figure 2. Trends in age-standardised (world population) death certification rates per 100 000 from kidney cancer in 20 selected European countries,
1960–99.+—+, males all ages; A—A, females, all ages; + - - - + males, 35–64 years; A- - -A, females, 35–64 years.
1133
Figure 3. Overall age-standardised (world population) death certification rates per 100 000 (A) males and (B) females from kidney cancer in 1995–99
(unless otherwise specified in parentheses) in 35 selected European countries, and the European Union.
Table 2. Age-adjusted (world population) mortality rates from kidney cancer per 100 000 men and women aged from 35 to 64 years in separate
European countries in 1990, 1995 and 1999, and corresponding change in rates
Men Women








Austria 7.97 6.14 6.03 22.96 1.79 3.02 2.25 2.83 25.50 25.78
Belgium (1992) 5.35 5.71 – 6.73 – 1.96 2.79 – 42.35 –
Bulgaria 2.93 4.88 6.38 66.55 30.74 1.69 1.98 1.91 17.16 3.54
Croatia 5.04 7.03 6.86 39.48 2.42 2.75 2.17 2.17 21.09 0.00
Czech Republic 17.10 14.53 14.18 15.03 2.41 7.09 6.76 5.15 4.65 23.82
Denmark (1998) 7.66 6.99 6.74 8.75 3.58 4.77 3.61 3.08 24.32 14.68
Estonia – 12.00 10.03 – 16.42 – 5.00 3.97 – 20.60
Finland 9.16 7.17 6.10 21.72 14.92 4.38 3.08 2.40 29.68 22.08
France 6.01 5.45 5.64 9.32 3.49 2.37 2.27 2.23 4.22 1.76
Germany 8.60 8.11 6.02 5.70 25.77 3.87 3.42 2.36 11.63 30.99
Greece 3.15 3.26 3.27 3.49 0.31 1.25 0.98 1.07 21.60 9.18
Hungary 10.10 9.05 9.60 10.40 6.08 3.79 3.92 4.16 3.43 6.12
Ireland 3.30 3.81 5.96 15.45 56.43 2.15 1.97 2.31 8.37 17.26
Italy 5.83 5.34 4.81 8.40 9.93 2.17 1.88 1.68 13.36 10.64
Lithuania – 14.35 10.44 – 27.25 – 4.48 4.14 – 7.59
Luxembourg 5.05 4.93 4.74 2.38 3.85 3.72 1.19 0.00 68.01 100.00
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Table 2. (Continued)
Men Women








Macedonia – 0.89 3.49 – 292.13 – 0.32 1.37 – 328.13
Malta 3.70 8.20 5.06 121.62 38.29 2.95 1.55 1.39 47.46 10.32
Netherlands 7.51 6.39 6.16 14.91 3.60 2.61 3.45 2.96 32.18 14.20
Norway 6.20 7.05 7.24 13.71 2.70 4.03 2.28 2.04 43.42 10.53
Portugal 2.49 3.57 2.71 43.37 24.09 1.48 1.14 1.03 22.97 9.65
Slovakia – 10.87 9.69 – 10.86 – 3.93 4.39 – 11.70
Slovenia 5.11 6.25 7.09 22.31 13.44 2.52 3.25 1.48 28.97 54.46
Spain 3.42 3.97 4.12 16.08 3.78 1.08 1.64 1.70 51.85 3.66
Sweden 6.79 4.65 4.65 31.52 0.00 4.21 3.64 3.69 13.54 1.37
Switzerland 5.58 5.44 – 2.51 – 2.71 1.71 – 36.90 –
UK 6.16 5.78 6.00 6.17 3.81 2.59 2.92 2.26 12.74 22.60
European Union 6.34 5.94 5.38 6.31 9.43 2.64 2.56 2.14 3.03 16.41
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